|
1
|
Hoyert DL, Heron MP, Murphy SL and Kung
HC: Deaths: Final data for 2003. Natl Vital Stat Rep. 54:1–120.
2006.PubMed/NCBI
|
|
2
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shrikhande SV, Kleeff J, Reiser C, Weitz
J, Hinz U, Esposito I, Schmidt J, Friess H and Büchler MW:
Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann
Surg Oncol. 14:118–127. 2007. View Article : Google Scholar
|
|
4
|
Bilimoria KY, Bentrem DJ, Ko CY, Stewart
AK, Winchester DP and Talamonti MS: National failure to operate on
early stage pancreatic cancer. Ann Surg. 246:173–180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hay ED: An overview of
epithelio-mesenchymal transformation. Acta Anat (Basel). 154:8–20.
1995. View Article : Google Scholar
|
|
8
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grünert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Satoh K, Hamada S and Shimosegawa T:
Involvement of epithelial to mesenchymal transition in the
development of pancreatic ductal adenocarcinoma. J Gastroenterol.
50:140–146. 2015. View Article : Google Scholar
|
|
12
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cano CE, Motoo Y and Iovanna JL:
Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.
Sci World J. 10:1947–1957. 2010. View Article : Google Scholar
|
|
16
|
Browne G, Sayan AE and Tulchinsky E: ZEB
proteins link cell motility with cell cycle control and cell
survival in cancer. Cell Cycle. 9:886–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gunasinghe NP, Wells A, Thompson EW and
Hugo HJ: Mesenchymal-epithelial transition (MET) as a mechanism for
metastatic colonisation in breast cancer. Cancer Metastasis Rev.
31:469–478. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tiwari N, Tiwari VK, Waldmeier L, Balwierz
PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schübeler D, van
Nimwegen E and Christofori G: Sox4 is a master regulator of
epithelial-mesenchymal transition by controlling Ezh2 expression
and epigenetic reprogramming. Cancer Cell. 23:768–783. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tavazoie SF, Alarcón C, Oskarsson T, Padua
D, Wang Q, Bos PD, Gerald WL and Massagué J: Endogenous human
microRNAs that suppress breast cancer metastasis. Nature.
451:147–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kondo M, Yamamoto H, Nagano H, Okami J,
Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, et al:
Increased expression of COX-2 in nontumor liver tissue is
associated with shorter disease-free survival in patients with
hepatocellular carcinoma. Clin Cancer Res. 5:4005–4012. 1999.
|
|
21
|
Nishida N, Nagahara M, Sato T, Mimori K,
Sudo T, Tanaka F, Shibata K, Ishii H, Sugihara K, Doki Y, et al:
Microarray analysis of colorectal cancer stromal tissue reveals
upregulation of two oncogenic miRNA clusters. Clin Cancer Res.
18:3054–3070. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmittgen TD, Jiang J, Liu Q and Yang L:
A high-throughput method to monitor the expression of microRNA
precursors. Nucleic Acids Res. 32:e432004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Restivo A, Piacentini G, Placidi S,
Saffirio C and Marino B: Cardiac outflow tract: A review of some
embryogenetic aspects of the conotruncal region of the heart. Anat
Rec A Discov Mol Cell Evol Biol. 288:936–943. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lioubinski O, Müller M, Wegner M and
Sander M: Expression of Sox transcription factors in the developing
mouse pancreas. Dev Dyn. 227:402–408. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aaboe M, Birkenkamp-Demtroder K, Wiuf C,
Sørensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjøt L and
Ørntoft T: SOX4 expression in bladder carcinoma: Clinical aspects
and in vitro functional characterization. Cancer Res. 66:3434–3442.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu P, Ramachandran S, Ali Seyed M,
Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW,
Jaye DL, et al: Sex-determining region Y box 4 is a transforming
oncogene in human prostate cancer cells. Cancer Res. 66:4011–4019.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao YL, Sun YM, Chau GY, Chau YP, Lai TC,
Wang JL, Horng JT, Hsiao M and Tsou AP: Identification of SOX4
target genes using phylogenetic footprinting-based prediction from
expression microarrays suggests that overexpression of SOX4
potentiates metastasis in hepatocellular carcinoma. Oncogene.
27:5578–5589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Scharer CD, McCabe CD, Ali-Seyed M, Berger
MF, Bulyk ML and Moreno CS: Genome-wide promoter analysis of the
SOX4 transcriptional network in prostate cancer cells. Cancer Res.
69:709–717. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sinner D, Kordich JJ, Spence JR, Opoka R,
Rankin S, Lin SC, Jonatan D, Zorn AM and Wells JM: Sox17 and Sox4
differentially regulate beta-catenin/T-cell factor activity and
proliferation of colon carcinoma cells. Mol Cell Biol.
27:7802–7815. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang W, Zhang J, Zhan X, Lin T, Yang M, Hu
J, Han B and Hu S: SOX4 is associated with poor prognosis in
cholangiocarcinoma. Biochem Biophys Res Commun. 452:614–621. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang L, Li Y, Yang X, Yuan H, Li X, Qi M,
Chang YW, Wang C, Fu W, Yang M, et al: ERG-SOX4 interaction
promotes epithelial-mesenchymal transition in prostate cancer
cells. Prostate. 74:647–658. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parvani JG and Schiemann WP: Sox4, EMT
programs, and the metastatic progression of breast cancers:
Mastering the masters of EMT. Breast Cancer Res. 15:R722013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marchesi I, Giordano A and Bagella L:
Roles of enhancer of zeste homolog 2: From skeletal muscle
differentiation to rhabdomyosarcoma carcinogenesis. Cell Cycle.
13:516–527. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sparmann A and van Lohuizen M: Polycomb
silencers control cell fate, development and cancer. Nat Rev
Cancer. 6:846–856. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Varambally S, Cao Q, Mani RS, Shankar S,
Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen H, Tu SW and Hsieh JT:
Down-regulation of human DAB2IP gene expression mediated by
polycomb Ezh2 complex and histone deacetylase in prostate cancer. J
Biol Chem. 280:22437–22444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani
RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, et al: Repression
of E-cadherin by the polycomb group protein EZH2 in cancer.
Oncogene. 27:7274–7284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Min J, Zaslavsky A, Fedele G, McLaughlin
SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE,
Beroukhim R, et al: An oncogene-tumor suppressor cascade drives
metastatic prostate cancer by coordinately activating Ras and
nuclear factor-kappaB. Nat Med. 16:286–294. 2010. View Article : Google Scholar : PubMed/NCBI
|
